DIANTHUS THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.81 USD | -0.96% |
|
+5.68% | +128.94% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 154.1 | 698.8 | - | - |
| Enterprise Value (EV) 1 | 154.1 | 375.6 | 170.6 | 698.8 |
| P/E ratio | -1.23 x | -12.3 x | -10.3 x | -8.52 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 54.5 x | 466 x | 302 x | 215 x |
| EV / Revenue | 54.5 x | 250 x | 73.8 x | 215 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -5.44 x | -2.03 x | -7.27 x |
| FCF Yield | - | -18.4% | -49.4% | -13.8% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 14,818 | 29,349 | - | - |
| Reference price 2 | 10.40 | 23.81 | 23.81 | 23.81 |
| Announcement Date | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 2.826 | 1.501 | 2.312 | 3.255 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -48.17 | -70.38 | -94.12 | -128.3 |
| Operating Margin | - | -1,704.67% | -4,690.42% | -4,071.32% | -3,941.8% |
| Earnings before Tax (EBT) 1 | - | -43.56 | -63.07 | -86.81 | -119.9 |
| Net income 1 | -28.48 | -43.56 | -63.07 | -86.81 | -119.9 |
| Net margin | - | -1,541.22% | -4,202.92% | -3,754.89% | -3,684.05% |
| EPS 2 | -7.100 | -8.450 | -1.937 | -2.302 | -2.795 |
| Free Cash Flow 1 | - | - | -69.06 | -84.19 | -96.16 |
| FCF margin | - | - | -4,602.26% | -3,641.75% | -2,954.24% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/1/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.924 | 0.457 | 0.3714 | 0.3764 | 0.3764 | 0.3764 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -15.76 | -12.96 | -14.68 | -16.54 | -18.69 | -20.48 |
| Operating Margin | -1,705.52% | -2,835.01% | -3,951.75% | -4,393.62% | -4,966.58% | -5,439.9% |
| Earnings before Tax (EBT) 1 | -14.76 | -10.56 | -13.5 | -14.47 | -16.65 | -18.45 |
| Net income 1 | -14.76 | -10.56 | -13.5 | -14.47 | -16.65 | -18.45 |
| Net margin | -1,597.73% | -2,311.38% | -3,635.81% | -3,843.68% | -4,422.85% | -4,901.81% |
| EPS 2 | -3.780 | - | -0.4380 | -0.4540 | -0.5180 | -0.5540 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/9/23 | 3/21/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 323 | 528 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -69.1 | -84.2 | -96.2 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 0.04 | 0.14 | 0.16 |
| Capex / Sales | - | - | 2.67% | 6.06% | 5.05% |
| Announcement Date | 8/1/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
23.81
USD
Average target price
50.17
USD
Spread / Average Target
+110.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +128.94% | 699M | |
| +2.93% | 108B | |
| +7.02% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- DNTH Stock
- Financials Dianthus Therapeutics, Inc.